PowerVision closes first tranche of Series D funding

PowerVision, Inc., a private company developing an accommodating intraocular lens, today announced the closing of the first tranche of its Series D funding round with participation from existing investors Venrock, Johnson & Johnson Development Corp., Medtronic, Advanced Technology Ventures, Lexington Capital and Frazier Healthcare Ventures.  The Company noted that it plans to raise up to an additional $10 million as part of this same financing round.  "We plan to invest the funds raised from this financing in advancing the growing body of clinical validation for our revolutionary FluidVision® intraocular lens, including completing the study that should enable us to obtain the CE Mark in Europe next year.  We plan to build on the positive results achieved in our pilot study which showed our FluidVision lens restored accommodative functionality in 20 patients who received the lens during cataract surgery," said PowerVision's President and CEO and Co-Founder, Barry Cheskin.

While the market for intraocular lens (IOL) implants continues to grow, exceeding three million procedures annually in the United States alone, patients who receive a conventional IOL all lose their ability to accommodate – to dynamically adjust focus to see at near and far as well as points in between. PowerVision's novel fluid-controlled accommodating intraocular lens technology uses fluid inside its lens in combination with natural muscle forces in the eye to create a shape change in the lens, restoring accommodative ability. The Company has proven in recent clinical trials that it can deliver excellent near, intermediate and distance vision with its new fully injectable accommodating device.  This is an unprecedented achievement, making it the first "true" accommodating IOL.  PowerVision's products are not yet approved or cleared for sale.

Source:

PowerVision, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring AI's role in transforming healthcare diagnosis and treatment